Janmahasatian Sarayut, Duffull Stephen B, Ash Susan, Ward Leigh C, Byrne Nuala M, Green Bruce
School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia.
Clin Pharmacokinet. 2005;44(10):1051-65. doi: 10.2165/00003088-200544100-00004.
Lean bodyweight (LBW) has been recommended for scaling drug doses. However, the current methods for predicting LBW are inconsistent at extremes of size and could be misleading with respect to interpreting weight-based regimens.
The objective of the present study was to develop a semi-mechanistic model to predict fat-free mass (FFM) from subject characteristics in a population that includes extremes of size. FFM is considered to closely approximate LBW. There are several reference methods for assessing FFM, whereas there are no reference standards for LBW.
A total of 373 patients (168 male, 205 female) were included in the study. These data arose from two populations. Population A (index dataset) contained anthropometric characteristics, FFM estimated by dual-energy x-ray absorptiometry (DXA - a reference method) and bioelectrical impedance analysis (BIA) data. Population B (test dataset) contained the same anthropometric measures and FFM data as population A, but excluded BIA data. The patients in population A had a wide range of age (18-82 years), bodyweight (40.7-216.5 kg) and BMI values (17.1-69.9 kg/m2). Patients in population B had BMI values of 18.7-38.4 kg/m2. A two-stage semi-mechanistic model to predict FFM was developed from the demographics from population A. For stage 1 a model was developed to predict impedance and for stage 2 a model that incorporated predicted impedance was used to predict FFM. These two models were combined to provide an overall model to predict FFM from patient characteristics. The developed model for FFM was externally evaluated by predicting into population B.
The semi-mechanistic model to predict impedance incorporated sex, height and bodyweight. The developed model provides a good predictor of impedance for both males and females (r2 = 0.78, mean error [ME] = 2.30 x 10(-3), root mean square error [RMSE] = 51.56 [approximately 10% of mean]). The final model for FFM incorporated sex, height and bodyweight. The developed model for FFM provided good predictive performance for both males and females (r2 = 0.93, ME = -0.77, RMSE = 3.33 [approximately 6% of mean]). In addition, the model accurately predicted the FFM of subjects in population B (r2 = 0.85, ME = -0.04, RMSE = 4.39 [approximately 7% of mean]).
A semi-mechanistic model has been developed to predict FFM (and therefore LBW) from easily accessible patient characteristics. This model has been prospectively evaluated and shown to have good predictive performance.
瘦体重(LBW)已被推荐用于药物剂量的换算。然而,目前预测LBW的方法在体型极端情况下并不一致,在解释基于体重的治疗方案时可能会产生误导。
本研究的目的是建立一个半机制模型,根据包括体型极端情况的人群的受试者特征来预测去脂体重(FFM)。FFM被认为与LBW非常接近。有几种评估FFM的参考方法,而LBW没有参考标准。
共有373例患者(168例男性,205例女性)纳入研究。这些数据来自两个人群。人群A(索引数据集)包含人体测量学特征、通过双能X线吸收法(DXA - 一种参考方法)估计的FFM和生物电阻抗分析(BIA)数据。人群B(测试数据集)包含与人群A相同的人体测量指标和FFM数据,但排除了BIA数据。人群A中的患者年龄范围广泛(18 - 82岁),体重(40.7 - 216.5 kg)和BMI值(17.1 - 69.9 kg/m²)。人群B中的患者BMI值为18.7 - 38.4 kg/m²。从人群A的人口统计学数据建立了一个预测FFM的两阶段半机制模型。对于第1阶段,建立了一个预测阻抗的模型,对于第2阶段,使用一个纳入预测阻抗的模型来预测FFM。这两个模型结合起来提供了一个根据患者特征预测FFM的总体模型。通过对人群B进行预测对所建立的FFM模型进行外部评估。
预测阻抗的半机制模型纳入了性别、身高和体重。所建立的模型对男性和女性的阻抗都是一个良好的预测指标(r² = 0.78,平均误差[ME] = 2.30×10⁻³,均方根误差[RMSE] = 51.56[约为平均值的10%])。FFM的最终模型纳入了性别、身高和体重。所建立的FFM模型对男性和女性都具有良好的预测性能(r² = 0.93,ME = -0.77,RMSE = 3.33[约为平均值的6%])。此外,该模型准确地预测了人群B中受试者的FFM(r² = 0.85,ME = -0.04,RMSE = 4.39[约为平均值的7%])。
已经建立了一个半机制模型,根据易于获取的患者特征来预测FFM(从而预测LBW)。该模型已经进行了前瞻性评估,并显示具有良好的预测性能。